{"product_id":"reta-10mg-15mg-20mg-30mg","title":"Retatrutide 5mg \/ 10mg \/ 15mg \/ 20mg \/ 30mg","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity Retatrutide in Australia (5mg \/ 10mg \/ 15mg \/ 20mg \/ 30mg). Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eAbout Retatrutide\u003c\/h2\u003e\n\u003cp\u003eRetatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R). Optic Labs supplies retatrutide as a high-purity lyophilised powder in 5mg, 10mg, 15mg, 20mg and 30mg vials, packaged for in vitro and preclinical laboratory research.\u003c\/p\u003e\n\n\u003cp\u003eEach batch is independently HPLC-tested for purity and identity, with certificates of analysis available on request.\u003c\/p\u003e\n\n\u003cp\u003eRetatrutide is one of the most actively studied compounds in the metabolic and obesity research literature, following published Phase 2 clinical trial data showing substantial reductions in body weight in human study populations. Optic Labs supplies retatrutide for laboratory research only — not for human consumption, clinical use, or any therapeutic application.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e Retatrutide (LY-3437943)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS number:\u003c\/strong\u003e 2381089-83-2\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular formula:\u003c\/strong\u003e C\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e343\u003c\/sub\u003eN\u003csub\u003e51\u003c\/sub\u003eO\u003csub\u003e61\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e ~4731.5 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMechanism (research context):\u003c\/strong\u003e Triple agonist — GLP-1R + GIP-R + GCG-R\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised (freeze-dried) white powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable sizes:\u003c\/strong\u003e 5mg, 10mg, 15mg, 20mg, 30mg vials\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store unreconstituted vials at 2–8°C; protect from light. Reconstituted solution stored at 2–8°C and used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eRetatrutide was developed as a successor compound to dual incretin agonists (such as tirzepatide), adding glucagon receptor agonism to the GLP-1\/GIP profile. Published preclinical and clinical research has examined retatrutide in the context of:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGLP-1, GIP and glucagon receptor binding, signalling and downstream pathways\u003c\/li\u003e\n\u003cli\u003eBody composition and adiposity in animal models\u003c\/li\u003e\n\u003cli\u003eEnergy expenditure and thermogenesis (glucagon-receptor contribution)\u003c\/li\u003e\n\u003cli\u003eHepatic lipid metabolism and NAFLD\/MASH research models\u003c\/li\u003e\n\u003cli\u003eGlycaemic control and insulin sensitivity in T2D models\u003c\/li\u003e\n\u003cli\u003ePhase 1 and Phase 2 clinical pharmacokinetic and weight-change studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a more detailed research summary with study citations, see our \u003ca href=\"\/blogs\/news\/retatrutide-triple-agonist-complete-guide\"\u003ecomplete retatrutide research guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/retatrutide-australia-triple-agonist-guide\"\u003eAustralian retatrutide guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/retatrutide-side-effects-clinical-trial-analysis\"\u003eclinical trial side-effects analysis\u003c\/a\u003e, and our \u003ca href=\"\/blogs\/news\/retatrutide-dosing-titration-protocol-guide\"\u003edosing and titration protocol research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eRetatrutide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in any laboratory protocol. A 10mg vial reconstituted in 2mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields a working concentration of 5mg\/mL; 1mL yields 10mg\/mL.\u003c\/p\u003e\n\n\u003cp\u003eLarger vial sizes scale proportionally. Exact volumes should be calculated for each protocol — our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e walks through the maths. Reconstituted vials should be stored refrigerated at 2–8°C and protected from light.\u003c\/p\u003e\n\n\u003ch2\u003eComparisons and related research compounds\u003c\/h2\u003e\n\u003cp\u003eRetatrutide sits within the broader class of incretin and metabolic peptides. Researchers may also be interested in:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/aod-9604-5mg\"\u003eAOD-9604\u003c\/a\u003e — fragment growth-hormone analogue, fat-loss research\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tesamorelin-10mg\"\u003eTesamorelin\u003c\/a\u003e — GHRH analogue, lipolysis research\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/cjc-1295-no-dac-ipamorelin-10mg\"\u003eCJC-1295 + Ipamorelin\u003c\/a\u003e — growth-hormone-releasing research peptide combination\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/5-amino-1mq-10mg\"\u003e5-Amino-1MQ\u003c\/a\u003e — NNMT inhibitor, metabolic research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a direct comparison between AOD-9604 and retatrutide research profiles, see our \u003ca href=\"\/blogs\/news\/aod-9604-vs-retatrutide\"\u003eAOD-9604 vs retatrutide article\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs retatrutide legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eRetatrutide is not currently approved by the Therapeutic Goods Administration (TGA) for therapeutic use in Australia — the compound remains in clinical-trial development. Optic Labs supplies retatrutide strictly as a research chemical for in vitro and preclinical laboratory research — not for human consumption, clinical use or any therapeutic application. For a detailed overview, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003eguide to peptide legality and TGA compliance in Australia\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is retatrutide?\u003c\/h3\u003e\n\u003cp\u003eRetatrutide (LY-3437943) is a synthetic 39-amino-acid peptide developed as a triple agonist of the GLP-1, GIP and glucagon receptors. In published research it has been investigated for its effects on body composition, glycaemic control, hepatic lipid metabolism and energy expenditure. See our \u003ca href=\"\/blogs\/news\/retatrutide-triple-agonist-complete-guide\"\u003ecomplete research guide\u003c\/a\u003e for background.\u003c\/p\u003e\n\n\u003ch3\u003eHow does retatrutide differ from semaglutide and tirzepatide?\u003c\/h3\u003e\n\u003cp\u003eSemaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP agonist. Retatrutide adds a third receptor target — the glucagon receptor — making it a triple agonist. The published research literature suggests glucagon-receptor agonism contributes to energy expenditure effects beyond what is seen with GLP-1 alone or GLP-1 + GIP. Our \u003ca href=\"\/blogs\/news\/retatrutide-triple-agonist-complete-guide\"\u003eresearch guide\u003c\/a\u003e covers the comparisons.\u003c\/p\u003e\n\n\u003ch3\u003eHow is retatrutide supplied?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs supplies retatrutide as a lyophilised powder in glass research vials, available in 5mg, 10mg, 15mg, 20mg and 30mg sizes. Each vial is sealed and shipped with a tamper-evident seal. Certificates of analysis showing HPLC purity testing are available on request.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a retatrutide vial?\u003c\/h3\u003e\n\u003cp\u003eReconstitution volume depends on the vial size and the working concentration required by the research protocol. As a starting reference: 10mg in 2mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields 5mg\/mL; 20mg in 2mL yields 10mg\/mL. Our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution guide\u003c\/a\u003e covers the calculations across all vial sizes.\u003c\/p\u003e\n\n\u003ch3\u003eHow should reconstituted retatrutide be stored?\u003c\/h3\u003e\n\u003cp\u003eUnreconstituted vials should be stored at 2–8°C and protected from light. Once reconstituted, the solution should be refrigerated at 2–8°C and used within approximately 30 days. For full storage protocols, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease.\u003c\/p\u003e\n\n\u003cp\u003eOptic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"5mg","offer_id":53364520157368,"sku":null,"price":94.99,"currency_code":"AUD","in_stock":true},{"title":"10mg","offer_id":53360883630264,"sku":null,"price":142.99,"currency_code":"AUD","in_stock":false},{"title":"15mg","offer_id":53360883663032,"sku":null,"price":180.99,"currency_code":"AUD","in_stock":false},{"title":"20mg","offer_id":53360883695800,"sku":null,"price":213.99,"currency_code":"AUD","in_stock":true},{"title":"30mg","offer_id":53360883728568,"sku":null,"price":265.99,"currency_code":"AUD","in_stock":true},{"title":"60mg","offer_id":53474336899256,"sku":null,"price":359.99,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0952\/4196\/1656\/files\/reta5.png?v=1776426193","url":"https:\/\/opticlabsau.com\/products\/reta-10mg-15mg-20mg-30mg","provider":"Optic Labs","version":"1.0","type":"link"}